MeiraGTx Holdings plc (NASDAQ:MGTX) CEO Alexandria Forbes Sells 35,839 Shares

MeiraGTx Holdings plc (NASDAQ:MGTX) CEO Alexandria Forbes sold 35,839 shares of the company’s stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $6.47, for a total transaction of $231,878.33. Following the completion of the sale, the chief executive officer now owns 1,395,102 shares of the company’s stock, valued at approximately $9,026,309.94. This trade represents a 2.50 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

MeiraGTx Stock Performance

NASDAQ:MGTX opened at $6.20 on Friday. The company has a debt-to-equity ratio of 0.86, a current ratio of 2.34 and a quick ratio of 2.34. The firm has a market cap of $484.55 million, a price-to-earnings ratio of -5.12 and a beta of 1.26. The firm’s fifty day moving average price is $6.28 and its 200 day moving average price is $5.12. MeiraGTx Holdings plc has a 1-year low of $3.85 and a 1-year high of $7.37.

Institutional Trading of MeiraGTx

Several hedge funds have recently made changes to their positions in the company. JPMorgan Chase & Co. raised its holdings in MeiraGTx by 1.2% during the third quarter. JPMorgan Chase & Co. now owns 342,667 shares of the company’s stock worth $1,429,000 after purchasing an additional 4,186 shares in the last quarter. Garden State Investment Advisory Services LLC purchased a new position in shares of MeiraGTx during the 3rd quarter worth approximately $1,636,000. Barclays PLC raised its stake in shares of MeiraGTx by 107.1% during the 3rd quarter. Barclays PLC now owns 147,827 shares of the company’s stock worth $618,000 after buying an additional 76,437 shares in the last quarter. State Street Corp lifted its holdings in shares of MeiraGTx by 0.9% in the 3rd quarter. State Street Corp now owns 574,727 shares of the company’s stock valued at $2,397,000 after buying an additional 5,251 shares during the period. Finally, Erste Asset Management GmbH purchased a new stake in shares of MeiraGTx in the third quarter valued at approximately $2,795,000. Institutional investors and hedge funds own 67.48% of the company’s stock.

Wall Street Analysts Forecast Growth

MGTX has been the topic of a number of recent research reports. Chardan Capital restated a “buy” rating and issued a $36.00 price objective on shares of MeiraGTx in a research note on Monday, November 18th. Royal Bank of Canada boosted their price target on MeiraGTx from $9.00 to $11.00 and gave the company an “outperform” rating in a research report on Thursday, November 14th.

About MeiraGTx

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia.